Why nursing homes and hospice are so expensive in the U.S.

Why nursing homes and hospice are so expensive in the U.S.


Baby boomers are about to be the largest generation in American history to hit the long-term care space. Born between 1946 and 1964, as defined by Pew Research, the oldest baby boomers are turning 80 next year. The group is set to flood a senior care space that is already understaffed, underfunded and facing political uncertainty.

“This space is completely underprepared for the number of older adults that are going to need long term care and end of life care,” said David Grabowski, professor of health care policy at Harvard Medical School. “We’ve historically relied heavily on families. There’s not going to be the number of family members that we’ve had in the past.”

Now private equity is increasingly looking to get in on the market. A recent study found between 2015 to 2022, 47 private equity firms bought 124 U.S. hospice agencies. Today an estimated 75% of U.S. hospice agencies are for-profit, according to a study out of the University of Pennsylvania.

“Hospice was started as a grassroots, nonprofit movement where the majority of care, a couple decades back, was provided by strictly non-profits,” said Robert Tyler Braun, assistant professor in the division of health policy and economics at Weill Cornell Medicine. “In this current landscape now, the majority of hospice providers are for profit.”

Nursing homes and long-term care facilities have long been an acquisition target for private equity and publicly traded companies. Data provided to CNBC by Coherent Market Insights shows those same trends in the hospice care space have picked up significantly since the 2010s.

Watch the video above to learn how these investments are impacting the space, who is investing in it, and what it means for seniors and their families.



Source

Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More
Patient advocacy groups urge U.S. court to halt overseas prescription drug operations
Health

Patient advocacy groups urge U.S. court to halt overseas prescription drug operations

In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York. Spencer Platt | Getty Images News | Getty Images A coalition of patient advocacy groups is urging a federal court to halt the practices of third-party companies that buy drugs from countries outside the FDA-regulated […]

Read More